

### Happy New Year from the Synergic Family!

As we welcome 2025, we want to reflect on the strides we've made in the past year and share some exciting milestones ahead.

### Celebrating Progress in Parkinson's Research and Therapy

2024 was a great year for Synergic as we made significant progress in bringing the VT Touch closer to market. With our breakthrough device designation from the FDA, announced in early 2023, we've continued to pursue our mission to enhance the quality of life for those living with Parkinson's disease.



## Clinical Trials Update

Our pivotal clinical trial is progressing well, and we are still enrolling participants who live in the Portland, Oregon area. Improvements in quality of life and independence observed in our longitudinal trial have shown promising results we expect to see repeated in this study.

## Advancements in Vibrotactile Therapy

Synergic presented our work on Coordinated Reset Vibrotactile Therapy for the Treatment of Bradykinesia in Parkinson's Disease Patients at the prestigious Movement Disorder Conference in Philadelphia. The study demonstrated significant improvements in motor symptoms, particularly bradykinesia, with this innovative therapy. These findings underline the potential of CR Vibrotactile Therapy as a transformative, non-invasive treatment option for Parkinson's disease.

[\[Read the abstract here\]](#)

## The Role of Exercise and Support

While our technology continues to progress, we emphasize the importance of regular exercise and participation in support groups. Both have been shown to positively impact the progression of Parkinson's symptoms and enhance overall well-being.

Stay tuned for updates and thank you for being part of our journey to improve the lives of people with Parkinson's.

